Skip to main content
S 1522 118th Congress Senate Health

A bill to require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable.

Introduced: May 10, 2023 Introduced by: Marshall, Roger Republican · Kansas See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 10, 2023
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
May 10, 2023
Introduced in Senate
 Plain-English summary Congressional Research Service

This bill requires the Food and Drug Administration to report on its designation of biosimilars as interchangeable, including the applicable standards, authorities, evidence, and other factors involved in such designations. (Biosimilars that are designated as interchangeable may be substituted for the reference product at a pharmacy without a new prescription, depending on state pharmacy laws.)

What's happening now May 10, 2023

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Committees of jurisdiction 1